{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"11"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"120"},{"groupId":"OG001","value":"61"}],"units":"Participants"}],"description":"Corticosteroid-free remission defined as being in clinical remission by modified Mayo score in addition to not requiring any treatment with corticosteroid for at least 8 weeks at Week 54, among the patients who used oral corticosteroids at baseline. Patients with dose adjustment to CT-P13 SC 240 mg prior to Week 54 were considered as non-remitter.","groups":[{"description":"CT-P13 SC 120 mg","id":"OG000","title":"CT-P13 SC 120 mg"},{"description":"Placebo","id":"OG001","title":"Placebo"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Patients who used oral corticosteroids at baseline among the All-randomized population","reportingStatus":"POSTED","timeFrame":"Week 54","title":"Percentage of Patients Achieving Corticosteroid-Free Remission at Week 54","type":"SECONDARY","unitOfMeasure":"Participants"}